Although ‘new’ biologic therapies are used for many autoimmune conditions, there have been several notable setbacks in SLE [9], with only belimumab, a monoclonal antibody targeting the B lymphocyte stimulator (BLYS), licensed for SLE (across ages) in over 50 years [10, 11]. This evidence concerns the gene TNFSF13B and systemic lupus erythematosus.